XTalks

JANUARY 21, 2025

From non-invasive cancer diagnostics to life-saving cardiovascular implants, the latest medical devices cleared or approved by the FDA in 2024 reflect the remarkable strides in science and engineering. In this blog, we discuss some of these new medical devices of 2024 that have improved patient outcomes and enhanced quality of life worldwide.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

XTalks

JANUARY 22, 2021

It identifies bacteria using both genotypic and phenotypic assessments within 1.5 Lee said, “Global research shows that 50 percent usage of antibiotics is inappropriate, and empirical treatment is one of the main causes. MedFluid’s in vitro diagnostic (IVD) platform fAST is based on microfluidics as its core technology.

Bacteria 52

Bacteria In-Vitro Genotype Marketing 52

The Pharma Data

MARCH 16, 2022

Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, It’s critical to quickly and accurately identify variants to inform ongoing research – including the ongoing development of therapeutics and vaccines. 3 and Delta. “In

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

Roots Analysis

AUGUST 12, 2024

It is worth mentioning that molecular diagnostics is a subset of the broader in vitro diagnostics market. According to the World Health Organization, there are over 40,000 in vitro diagnostics products available in the market. Such test can be used for gene expression profiling, genotyping and detecting chromosomal abnormalities.

Genetics 40

Genetics Gene Expression RNA DNA 40

The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. which will remain a key shareholder. SciNeuro Pharmaceuticals. in a statement. . Libra Therapeutics.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. A solution could be at hand with Overland Pharmaceuticals. Below is a roundup of some of this week’s interesting news.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52